Fig. 3

Kaplan–Meier curves of escalation to triple therapy (fixed-dose or concurrent LAMA/LABA/ICS) for the hdPS-matched cohort. Data are shown for the prespecified study period (1 April 2015 to 31 March 2019) (a) and the post hoc extension period (1 April 2015 to 31 March 2020) (b). CI confidence interval, hdPS high-dimensional propensity score, HR hazard ratio, ICS inhaled corticosteroid, LABA long-acting β2-agonist, LAMA long-acting muscarinic antagonist, Tio tiotropium, Tio/Olo tiotropium/olodaterol